A 3-month-old boy is brought to the physician by his parents because of a 2-day history of poor feeding and lethargy. He was born at term and has had three episodes of bilateral otitis media since birth. Umbilical cord separation occurred at the age of 8 weeks. He is at the 30th percentile for height and 20th percentile for weight. His temperature is 39.0°C (102.2°F) and blood pressure is 58/36 mm Hg. Physical examination shows white oral patches and confluent scaly erythematous skin lesions in the groin. Laboratory studies show a leukocyte count of 41,300/mm3 (92% segmented neutrophils and 8% lymphocytes) and a platelet count of 224,000/mm3. Blood cultures at 20°C (68°F) grow catalase-positive yeast cells. Which of the following is the most likely underlying cause of this patient's symptoms? Which of the following is the most likely diagnosis? (Choice A) A defective CD40 ligand is the underlying mechanism of type 1 hyper-IgM syndrome, which typically manifests with recurrent infections during the first 2 years of life. However, neutropenia rather than neutrophilia is typically seen, and patients often show failure to thrive. Delayed umbilical cord separation would also not be expected. (Choice B) Leukocyte adhesion deficiency type 1 (LAD1) is caused by an autosomal recessive defect in CD18 (beta-2 integrin), which prevents leukocyte migration to the site of infection. As a result, patients have recurrent mucocutaneous infections that can progress to sepsis and a characteristic absence of pus or neutrophils at the site of infection. Other features of the condition include poor wound healing with large skin ulcers, delayed separation of the umbilical cord due to omphalitis, and severe periodontitis/gingivitis. A very high neutrophil count (as high as 100,000/mm3 during active infection) is seen because neutrophil activation and recruitment of neutrophils from the non-circulating pool occurs. However, neutrophils are unable to extravasate into tissues, causing pooling within the circulation. LAD1 is diagnosed using flow cytometric measurement of surface molecules such as CD11b or CD18. The treatment for mild to moderate cases is mainly supportive, with early treatment of infections and prophylaxis with trimethoprim-sulfamethoxazole if needed, but severe cases require definitive therapy with hematopoietic stem cell transplantation. (Choice C) A defect in the interleukin-2 receptor subunit gamma gene (IL2RG) is the most common mutation associated with severe combined immunodeficiency (SCID), which can manifest soon after birth with recurrent episodes of otitis media, candidiasis, and sepsis. However, patients would also typically show failure to thrive and have a history of chronic diarrhea. A CBC, moreover, would reveal a low absolute lymphocyte count (< 1000/mm3). Delayed umbilical cord separation would not be expected. (Choice D) A defect in Bruton tyrosine kinase (BTK) is responsible for X-linked agammaglobulinemia (XLA), which may result in recurrent otitis media from infection with extracellular bacteria such as S. pneumoniae and H. influenzae. However, infants with B-cell defects such as XLA typically do not develop symptoms before 3–6 months because they generally retain passively acquired maternal antibodies up to this age. Delayed umbilical cord separation would also not **wait
| Clinical Feature | Explanation in LAD1 |
|---|---|
| Delayed umbilical cord separation (8 weeks) | Classic hallmark; neutrophils cannot migrate into the cord stump to clear bacteria (normal separation is 1–2 weeks) |
| Recurrent infections since birth (3× otitis media) | Neutrophils can be recruited but cannot leave the bloodstream to fight infection at mucosal/tissue sites |
| Oral candidiasis (white patches) + groin dermatitis | Recurrent mucocutaneous infections with both bacteria and fungi due to absent neutrophil tissue infiltration |
| Markedly elevated WBC (41,300/mm³, 92% neutrophils) | Neutrophils are activated and released from the marginating pool but cannot extravasate → pool in circulation, causing dramatic leukocytosis (can reach >100,000/mm³ during infection) |
| Catalase-positive yeast on blood culture at 20°C | Consistent with Candida or Malassezia — organisms that normally require intact phagocyte defense |
| Sepsis (fever 39°C, BP 58/36) | Infections rapidly progress to bacteremia/fungemia because tissue neutrophil defense is absent |
| Choice | Diagnosis | Why Excluded |
|---|---|---|
| A | Hyper-IgM syndrome (CD40L defect) | Causes neutropenia, not neutrophilia; no delayed cord separation |
| C | SCID (IL2RG defect) | Lymphopenia expected (lymphocytes <1,000/mm³); this patient has 8% lymphocytes but the absolute count from 41,300 × 8% ≈ 3,300 — above the SCID threshold; no delayed cord separation |
| D | X-linked agammaglobulinemia (BTK defect) | Symptoms do not appear before 3–6 months due to maternal antibody protection; this infant is already symptomatic at 3 months with cord separation delay and candidiasis — inconsistent with pure B-cell defect |
delayed separation of the umbilical cord due to omphalitis, and severe periodontitis/gingivitis. A very high neutrophil count (as high as 100,000/mm3 during active infection) is seen because neutrophil activation and recruitment of neutrophils from the non-circulating pool occurs. However, neutrophils are unable to extravasate into tissues, causing pooling within the circulation. LAD1 is diagnosed using flow cytometric measurement of surface molecules such as CD11b or CD18. The treatment for mild to moderate cases is mainly supportive, with early treatment of infections and prophylaxis with trimethoprim-sulfamethoxazole if needed, but severe cases require definitive therapy with hematopoietic stem cell transplantation. (Choice C) A defect in the interleukin-2 receptor subunit gamma gene (IL2RG) is the most common mutation associated with severe combined immunodeficiency (SCID), which can manifest soon after birth with recurrent episodes of otitis media, candidiasis, and sepsis. However, patients would also typically show failure to thrive and have a history of chronic diarrhea. A CBC, moreover, would reveal a low absolute lymphocyte count (< 1000/mm3). Delayed umbilical cord separation would not be expected. (Choice D) A defect in Bruton tyrosine kinase (BTK) is responsible for X-linked agammaglobulinemia (XLA), which may result in recurrent otitis media from infection with extracellular bacteria such as S. pneumoniae and H. influenzae. However, infants with B-cell defects such as XLA typically do not develop symptoms before 3–6 months because they generally retain passively acquired maternal antibodies up to this age. Delayed umbilical cord separation would also not be expected. Moreover, candidiasis is more commonly seen in defects involving T cells and granulocytes than in isolated primary defects of antibody production such as XLA. (Choice E) Defective NADPH oxidase results in chronic granulomatous disease (CGD), which may manifest in infancy with candidiasis (since C. albicans is catalase-positive) and neutrophilia during episodes of infection. However, these infections tend to remain localized, and sepsis is not as common as in other primary immune deficiency syndromes. Other pathognomonic features of CGD include GI obstruction and urinary retention caused by granulomas. Delayed umbilical cord separation would not be expected. (Choice F) Defective microtubules due to a loss of function of the lysosomal trafficking regulator gene (LYST) is the underlying pathophysiology of Chediak-Higashi syndrome (CHS), which can result in systemic candidiasis. However, patients with CHS would have neutropenia, not neutrophilia. Features such as oculocutaneous albinism and/or ocular motility disorders (e.g., strabismus, nystagmus) would also be present. Delayed umbilical cord separation would not be expected. (Choice G) A defectively organized actin cytoskeleton due to a mutation in the WAS gene is the underlying cause of Wiskott-Aldrich syndrome (WAS), which can manifest in infancy with recurrent otitis media as well as scaly erythematous lesions in the diaper area due to atopic dermatitis. However, the absence of thrombocytopenia on a CBC essentially rules out WAS. Delayed umbilical cord separation would also not be expected. above 2 msgs merge and make hy usmle style topper level notes hy to revise the whole concept from the above question and option distractors ruling out
3-month-old boy | recurrent bilateral otitis media since birth | umbilical cord separation at 8 weeks | oral candidiasis + groin dermatitis | sepsis | WBC 41,300 (92% neutrophils) | blood culture → catalase-positive yeast
| Feature | LAD1 ✅ | Hyper-IgM (CD40L) | SCID (IL2RG) | XLA (BTK) | CGD (NADPH) | Chediak-Higashi (LYST) | Wiskott-Aldrich (WAS) |
|---|---|---|---|---|---|---|---|
| Gene/Defect | CD18 (β2-integrin) | CD40L (CD154) | IL2RG (γc chain) | BTK | NADPH oxidase | LYST (lysosomal trafficking) | WASp (actin cytoskeleton) |
| Inheritance | AR | XL | XL | XL | XL (most common) | AR | XL |
| Neutrophil count | Very HIGH (↑↑↑) | Low (neutropenia) | Low (lymphopenia; neutrophils nl) | Normal | High during infection | Low | Normal/Low |
| Lymphocyte count | Normal | Normal/↓ | Very LOW (<1000) | Normal (no B cells) | Normal | Normal | Normal/↓ |
| Delayed cord separation | YES ✅ | No | No | No | No | No | No |
| Catalase+ organism susceptibility | Yes (Candida) | No | Yes | No | Yes (Aspergillus, Candida, Staph, Burkholderia) | Partial | No |
| Candidiasis | Yes | No | Yes | Rare (T-cell intact) | Yes | Yes | No |
| Recurrent otitis media | Yes | Yes | Yes | Yes (S. pneumo, H. flu) | Less common | Less common | Yes |
| Onset of symptoms | Birth | 1st year | Birth | 3–6 months (maternal Ab) | Infancy | Infancy | Infancy |
| Thrombocytopenia | No | No | No | No | No | No | YES ✅ (small platelets) |
| Skin findings | Mucocutaneous infections, no pus | None specific | Diffuse infections | None specific | Granulomas | Oculocutaneous albinism | Eczema/atopic derm |
| Pathognomonic feature | Delayed cord; no pus at infection site; extreme leukocytosis | Opportunistic + bacterial infections; low IgG/A/E, high IgM | Failure to thrive, chronic diarrhea | Absent B cells/tonsils | GI/urinary granulomas; lymphadenopathy | Albinism + nystagmus/strabismus + giant granules in neutrophils | Triad: eczema + thrombocytopenia + immunodeficiency |
| Diagnosis | Flow cytometry (↓ CD11b/CD18) | Serum Ig levels; ↑ IgM, ↓ rest | Flow cytometry (absent T/B/NK) | Flow cytometry (absent B cells) | DHR flow cytometry / NBT test | Peripheral smear (giant granules) | CBC (↓ small platelets) + genetic |
| Definitive Tx | HSCT (severe) | HSCT | HSCT | IVIG + antibiotics | HSCT (severe) / IFN-γ (mild) | HSCT | HSCT |
Normal: Selectins → rolling → ICAM-1/LFA-1 → tight adhesion → diapedesis → tissue
LAD1: Selectins → rolling → [CD18 ABSENT] → NO tight adhesion → neutrophils TRAPPED in blood
| Neutrophil Count | Think |
|---|---|
| Extremely HIGH | LAD1, CGD (during infection) |
| Low (neutropenia) | Hyper-IgM, Chediak-Higashi |
| Normal | XLA, Wiskott-Aldrich |
| Not the key finding | SCID (lymphopenia is the key) |
| Condition | IgG | IgM | IgA | IgE |
|---|---|---|---|---|
| Hyper-IgM syndrome | ↓↓ | ↑↑ | ↓↓ | ↓↓ |
| XLA | ↓↓ | ↓↓ | ↓↓ | ↓↓ |
| SCID | ↓↓ | ↓↓ | ↓↓ | ↓↓ |
| Wiskott-Aldrich | ↓ IgM | Normal | ↑ IgA/IgE | ↑ |
| LAD1 | Normal | Normal | Normal | Normal |
| CGD | Normal | Normal | Normal | Normal |
| Buzz Word/Finding | Diagnosis |
|---|---|
| Delayed umbilical cord separation | LAD1 |
| Extreme leukocytosis, no pus at infection sites | LAD1 |
| High IgM, low IgG/IgA/IgE | Hyper-IgM |
| Lymphocyte count <1000, failure to thrive | SCID |
| Symptoms begin after 6 months, encapsulated bacteria | XLA |
| Catalase+ infections + granulomas + GI obstruction | CGD |
| Giant granules on smear + oculocutaneous albinism | Chediak-Higashi |
| Eczema + small platelets + recurrent infections | Wiskott-Aldrich |
| Absent tonsils/lymph nodes on exam | XLA |
| Pneumocystis in infancy | SCID or Hyper-IgM |
too much to process hy compsact set of rules and concept please
| Disease | Defect | Key Distinguisher |
|---|---|---|
| LAD1 | CD18 (β2-integrin) | Delayed cord + no pus + extreme neutrophilia |
| Hyper-IgM | CD40L | ↑IgM, ↓all others + neutropenia |
| SCID | IL2RG (γc chain) | Lymphocytes <1000 + failure to thrive + chronic diarrhea |
| XLA | BTK | Asymptomatic until 6 mo; no B cells/tonsils; encapsulated bacteria |
| CGD | NADPH oxidase | Catalase+ bugs + granulomas + GI/urinary obstruction |
| Chediak-Higashi | LYST | Albinism + giant granules on smear + neutropenia |
| Wiskott-Aldrich | WASp | Eczema + micro-thrombocytopenia + infections (triad) |
CD18 absent → no tight adhesion → neutrophils CAN'T leave blood
→ No pus at infection sites
→ Infections → rapid sepsis
→ Neutrophils pool in blood → WBC up to 100,000
→ Umbilical cord never cleared → separation delayed (>3 weeks)
but in this question the answer is b2 intergrin
| Name | What it is |
|---|---|
| CD18 | The gene/protein name |
| β2-integrin | The structural/functional name |
| LAD1 | The disease caused by its deficiency |
so can you So can you include such defects also in your high yield note, like you know defective beta-2 integrin, defective CD40 ligand, defective interleukin-2 receptor gamma chain, defective tyrosine kinase, defective NADPH oxidase, defective microtubules, defective actin cytoskeleton, all in which primary immune deficiencies can be related to. You can add that also in the above short mentioned high yield note. It will be very useful.
| Molecular Defect | Protein/Gene | Disease | Key Distinguisher |
|---|---|---|---|
| Defective β2-integrin | CD18 | LAD1 | Delayed cord + no pus + extreme neutrophilia |
| Defective CD40 ligand | CD154 | Hyper-IgM | ↑IgM, ↓all others + neutropenia |
| Defective IL-2 receptor γ-chain | IL2RG (γc) | SCID | Lymphocytes <1000 + FTT + chronic diarrhea |
| Defective Bruton tyrosine kinase | BTK | XLA | Asymptomatic until 6 mo; no B cells/tonsils |
| Defective NADPH oxidase | CYBB (gp91) | CGD | Catalase+ bugs + granulomas + GI obstruction |
| Defective microtubule function | LYST | Chediak-Higashi | Albinism + giant granules on smear + neutropenia |
| Defective actin cytoskeleton | WASp | Wiskott-Aldrich | Eczema + micro-thrombocytopenia + infections |
CD18 (β2-integrin) absent
→ No tight adhesion → neutrophils CAN'T leave blood
→ No pus at infection sites → rapid sepsis
→ Neutrophils pool in blood → WBC up to 100,000
→ Umbilical cord never cleared → separation delayed (>3 weeks)
| Disease | IgG | IgM | IgA/IgE |
|---|---|---|---|
| Hyper-IgM | ↓↓ | ↑↑ | ↓↓ |
| XLA | ↓↓ | ↓↓ | ↓↓ |
| SCID | ↓↓ | ↓↓ | ↓↓ |
| Wiskott-Aldrich | ↓ IgM | Normal | ↑ IgA/IgE |
| LAD1 / CGD / Chediak | Normal | Normal | Normal |
| Disease | Diagnostic Test |
|---|---|
| LAD1 | Flow cytometry → absent CD11b/CD18 |
| Hyper-IgM | Serum Ig levels (↑IgM, ↓rest) |
| SCID | Flow cytometry → absent T/B/NK cells |
| XLA | Flow cytometry → absent B cells; no tonsils |
| CGD | DHR flow cytometry or NBT test (no burst) |
| Chediak-Higashi | Peripheral smear → giant granules in neutrophils |
| Wiskott-Aldrich | CBC → small, low platelets + genetic testing |
A 2-year-old boy with a history of multiple hospitalizations for fever and infection undergoes immunologic evaluation. Serum CH50 assay shows inappropriately low erythrocyte lysis and further workup confirms C8 deficiency. This patient is at increased risk for recurrent infections with which of the following pathogens? Terminal complement deficiencies (C5–C9) impede the formation of the membrane attack complex, which renders affected patients more susceptible to Neisseria bacteremia (e.g., N. meningitidis and N. gonorrhoeae pyogenic infections). (Choice B) Individuals with an IgA deficiency (e.g., selective IgA deficiency or ataxia-telangiectasia) are at increased risk of Giardia lamblia infection. Giardiasis is not associated with terminal complement deficiency. (Choice C) Fungal infections, including Candida, are associated with impaired T-cell immunity and IL-17 defects. These can be detected by the absence of a reaction to cutaneous application of Candida antigen, or absent T-cell proliferation in vitro, but will not influence CH50 assay. Candida infections are not associated with terminal complement deficiency. (Choice D) Pneumocystis jirovecii infections are associated with hyper-IgM syndrome and significant T-cell dysfunction (e.g., in HIV). Hyper-IgM syndrome is characterized by decreased levels of IgG, IgA, and IgE, while IgM levels may be normal or increased. It does not influence CH50 assay, and Pneumocystis infections are not associated with terminal complement deficiency. (Choice E) Increased susceptibility to Nocardia and other catalase-positive species is seen in granulocyte deficiencies such as chronic granulomatous disease (CGD). CGD can be detected with flow cytometry (the tetrazolium dye reduction test is obsolete) but does not have an effect on CH50 assay. Nocardia infection is not associated with terminal complement deficiency. (Choice F) Mycobacterium infection is associated with decreased interferon gamma and interleukin-12 receptor deficiency. It is not associated with terminal complement deficiency. same as above HY compact question solving notes for usmle step `1 from above concepts and opton distractors
Terminal complement deficiency (C5–C9)
→ No MAC formation
→ Can't kill encapsulated gram-negatives with outer membrane
→ Susceptible to NEISSERIA (meningitidis + gonorrhoeae) ONLY
| Component Deficient | Disease/Consequence | Key Pathogen |
|---|---|---|
| C1, C2, C4 (classical) | SLE-like autoimmune disease | Not infection-focused |
| C3 | Recurrent ALL encapsulated bacteria | S. pneumo, H. flu, N. meningitidis |
| C5–C9 (terminal/MAC) | Neisseria bacteremia specifically | N. meningitidis, N. gonorrhoeae |
| DAF/CD59 | Paroxysmal nocturnal hemoglobinuria (PNH) | Hemolysis, not infection |
| MBL | Recurrent infections in early childhood | Encapsulated bacteria |
| C1-esterase inhibitor | Hereditary angioedema | No infection risk |
Rule: C3 = broad encapsulated bacteria susceptibility. C5–C9 = Neisseria only.
| Pathogen | Immune Defect | Disease |
|---|---|---|
| Neisseria | Terminal complement (C5–C9) ↓ | MAC deficiency |
| Giardia lamblia | IgA deficiency | Selective IgA def / Ataxia-telangiectasia |
| Candida | T-cell defect / IL-17 defect | SCID, DiGeorge, mucocutaneous candidiasis |
| Pneumocystis jirovecii | T-cell defect / CD40L defect | SCID, Hyper-IgM, HIV |
| Nocardia + catalase+ bugs | NADPH oxidase defect | CGD |
| Mycobacterium | IL-12 receptor / IFN-γ defect | Mendelian susceptibility to mycobacterial disease |
| S. pneumo, H. flu, N. meningitidis | Antibody / C3 / Spleen absent | XLA, C3 def, Asplenia |
| Aspergillus | Neutrophil defect | CGD, post-chemo neutropenia |
| Cryptosporidium | IgA deficiency / T-cell defect | Hyper-IgM (especially) |
| Test | What It Detects |
|---|---|
| CH50 assay (low) | Classical + terminal complement pathway defect |
| AH50 assay (low) | Alternative complement pathway defect |
| Flow cytometry (CD11b/CD18) | LAD1 |
| DHR / NBT test (no burst) | CGD (NADPH oxidase defect) |
| Serum Ig levels | XLA, Hyper-IgM, SCID |
| Cutaneous Candida antigen / T-cell proliferation | T-cell dysfunction |
| Absent tonsils on exam | XLA |
Key point: CGD and complement deficiencies are both detected by separate tests. CGD does NOT affect CH50. Complement deficiency does NOT affect NBT/DHR.
A 17-year-old girl comes to the physician because of a sore throat, fevers, and fatigue for the past 3 weeks. Her temperature is 37.8°C (100°F), pulse is 97/min, and blood pressure is 90/60 mm Hg. Examination of the head and neck shows cervical lymphadenopathy, pharyngeal erythema, enlarged tonsils with exudates, and palatal petechiae. The spleen is palpated 2 cm below the left costal margin. Her leukocyte count is 14,100/mm3 with 54% lymphocytes (12% atypical lymphocytes). Results of a heterophile agglutination test are positive. This patient is at increased risk for which of the following conditions?Rheumatic fever is a delayed inflammatory sequela of group A streptococcus (GAS) pharyngitis that typically affects individuals within 2–4 weeks of primary infection. While this patient has a sore throat as well as signs of pharyngitis and tonsillitis, she also presents with splenomegaly and has a positive heterophile agglutination test, which rather indicates infectious mononucleosis. (Choice B) Kaposi sarcoma is not caused by Epstein-Barr virus (human herpesvirus 4) responsible for this patient's mononucleosis, but a close relative, the human herpesvirus 8. However, both HHV-4 and HHV-8 are oncoviruses that can lead to malignancies. (Choice C) Risk factors for hepatocellular carcinoma (HCC) include viral hepatitis (primarily hepatitis B and C), chronic aflatoxin exposure, chronic alcohol use, and obesity. While viral hepatitis manifests with fatigue, as seen in this patient, patients would also experience signs of liver injury (abdominal pain, jaundice, and/or pruritus), which are absent in this patient. Furthermore, her pharyngitis, splenomegaly, and positive heterophile agglutination test are suggestive of infectious mononucleosis. HCC is not a complication of infectious mononucleosis. (Choice D) Hodgkin lymphoma (HL) is a potential complication of infectious mononucleosis caused by Epstein-Barr virus (EBV). Additional complications of EBV infection include non-Hodgkin lymphoma (e.g., Burkitt lymphoma, diffuse large B cell lymphoma, and primary CNS lymphoma in HIV-positive patients) and nasopharyngeal carcinoma. The pathophysiology of EBV-associated malignancy includes virus-induced expression of latent membrane protein 1 (LMP1), which constitutively activates NF-κB and kinases that drive cell proliferation. (Choice E) Mycotic aneurysms are a potential complication of infectious endocarditis or vascular trauma (e.g., intravenous drug use). Presentation varies depending on the anatomic location affected (e.g., peripheral aneurysm vs cerebral aneurysm). Although this patient has a fever, she has no abnormal cardiac findings or other signs of infectious endocarditis (e.g., Osler nodes or Janeway lesions). Furthermore, her pharyngitis, splenomegaly, and positive heterophile agglutination test are suggestive of infectious mononucleosis. Mycotic aneurysms are not a complication of EBV infection. notes as above
| Finding | Significance |
|---|---|
| Sore throat + fever + fatigue | Classic triad of mono |
| Cervical lymphadenopathy + exudative tonsillitis + palatal petechiae | EBV pharyngitis pattern |
| Splenomegaly | EBV dissemination |
| Atypical lymphocytes (12%) | Reactive CD8+ T cells fighting EBV-infected B cells |
| Positive heterophile agglutination (Monospot) | Confirms EBV/infectious mononucleosis |
EBV → infects B cells via CD21 (complement receptor)
→ B cells proliferate uncontrollably
→ CD8+ T cells react → atypical lymphocytes on smear
→ Latent infection persists lifelong
→ LMP1 protein → activates NF-κB → drives cell proliferation → MALIGNANCY
| Malignancy | Key Detail |
|---|---|
| Hodgkin Lymphoma | Reed-Sternberg cells; EBV most common trigger |
| Burkitt Lymphoma | t(8;14) MYC translocation; "starry sky" pattern; jaw mass in Africa |
| Diffuse Large B-Cell Lymphoma | Aggressive; EBV-associated |
| Primary CNS Lymphoma | HIV/immunocompromised patients specifically |
| Nasopharyngeal Carcinoma | Southeast Asian predominance; EBV-driven |
Mechanism for all: LMP1 → constitutive NF-κB activation → uncontrolled B-cell proliferation
| Condition | Why NOT this answer |
|---|---|
| Rheumatic fever | Sequela of GAS (group A Strep), not EBV. Monospot negative in GAS. |
| Kaposi sarcoma | HHV-8, not HHV-4 (EBV). Both are oncoviruses but different viruses. |
| Hepatocellular carcinoma | HBV/HCV/alcohol/aflatoxin — not EBV. No jaundice here either. |
| Mycotic aneurysm | Complication of infective endocarditis, not EBV. No cardiac findings here. |
| Virus | Cancer(s) |
|---|---|
| EBV (HHV-4) | Hodgkin lymphoma, Burkitt lymphoma, DLBCL, CNS lymphoma (HIV), nasopharyngeal CA |
| HHV-8 | Kaposi sarcoma, primary effusion lymphoma |
| HPV (16/18) | Cervical CA, oropharyngeal CA, anal CA |
| HBV/HCV | Hepatocellular carcinoma |
| HTLV-1 | Adult T-cell leukemia/lymphoma |
| H. pylori | Gastric adenocarcinoma, MALT lymphoma |
| MCPyV | Merkel cell carcinoma |
| Complication | Key Point |
|---|---|
| Splenic rupture | Most dangerous acute complication; avoid contact sports for 3–4 weeks |
| Airway obstruction | Massive tonsillar enlargement; use steroids |
| Ampicillin/amoxicillin rash | Diffuse maculopapular rash if given for "strep throat" misdiagnosis |
| Hodgkin/Burkitt lymphoma | Long-term oncologic risk via LMP1/NF-κB |
| Guillain-Barré / encephalitis | Rare neurologic complications |
A 68-year-old woman comes to the physician for a follow-up examination. Three months ago, she underwent heart transplantation for restrictive cardiomyopathy and was started on transplant rejection prophylaxis. Her pulse is 76/min and blood pressure is 148/82 mm Hg. Physical examination shows enlargement of the gum tissue. There is a well-healed scar on her chest. Serum studies show hyperlipidemia. The physician recommends removing a drug that decreases T cell activation by inhibiting the transcription of interleukin-2 from the patient's treatment regimen and replacing it with a different medication. Which of the following drugs is the most likely cause of the adverse effects seen in this patient?Sirolimus is an immunosuppressant drug that can be used for transplant rejection prophylaxis. It binds FK binding protein (FKBP) to form a complex that inhibits mTOR. This inhibition prevents activation of mTOR kinase, which leads to inhibition of interleukin-2 (IL-2) induced T cell proliferation and impaired B cell differentiation. Sirolimus does not inhibit the transcription of IL-2. Side effects of this drug include hypertension and hyperlipidemia, as seen in this patient. However, it is not known to cause gingival hyperplasia. Further important adverse effects of sirolimus include infection, malignancy, pancytopenia, and insulin resistance. (Choice B) Glucocorticoids such as prednisolone are commonly used for transplant rejection prophylaxis. They exert their immunosuppressant effect via various mechanisms of action, including inhibition of NF-κB, suppression of T cell proliferation, and induction of apoptosis in lymphocytes. Glucocorticoids have a wide range of side effects including hypertension and hyperlipidemia, as seen in this patient. However, this group of drugs is not known to cause gingival hyperplasia. (Choice C) Tacrolimus is an immunosuppressant drug that is commonly used for transplant rejection prophylaxis. It binds FK binding protein (FKBP) to form a complex that inhibits calcineurin. Inhibition of calcineurin blocks activation of the NFAT transcription factors, which prevents interleukin-2 transcription and, as a result, decreases T cell activation. Side effects of this drug include hypertension and hyperlipidemia, as seen in this patient. However, it is not known to cause gingival hyperplasia. Further important adverse effects instead include infection, malignancy, new-onset diabetes mellitus, nephrotoxicity, and neurotoxicity. Although the mechanism of action of tacrolimus is consistent with the drug that the physician recommended to remove from this patient's treatment regimen, the reported adverse effects are more likely caused by a different medication. (Choice D) Cyclosporine is an immunosuppressant drug that is commonly used for transplant rejection prophylaxis. It binds cyclophilin to form a complex that inhibits calcineurin. Inhibition of calcineurin blocks activation of the NFAT transcription factors, which prevents interleukin-2 transcription and, as a result, decreases T cell activation. Cyclosporine is the only calcineurin inhibitor to cause gingival hyperplasia, so it is most likely the drug that was used in this patient. Further important side effects of cyclosporine include increased susceptibility to infection and increased risk for malignancy. (Choice E) Azathioprine is an immunosuppressant drug that can be used for transplant rejection prophylaxis. Azathioprine is a precursor of 6-mercaptopurine, an antimetabolite that blocks purine synthesis
| Drug | Binds | Inhibits | Mechanism | Unique Side Effects |
|---|---|---|---|---|
| Cyclosporine | Cyclophilin | Calcineurin → ↓NFAT → ↓IL-2 transcription | ↓ T-cell activation | Gingival hyperplasia, nephrotoxicity, HTN, hyperlipidemia, hirsutism |
| Tacrolimus | FKBP | Calcineurin → ↓NFAT → ↓IL-2 transcription | ↓ T-cell activation | New-onset DM, nephrotoxicity, neurotoxicity, HTN, hyperlipidemia — NO gingival hyperplasia |
| Sirolimus | FKBP | mTOR → ↓IL-2 induced proliferation | ↓ T-cell proliferation (not transcription) | HTN, hyperlipidemia, pancytopenia, insulin resistance — NO gingival hyperplasia |
| Azathioprine | — | Purine synthesis (via 6-MP) | ↓ DNA synthesis → ↓ lymphocyte proliferation | Bone marrow suppression, pancreatitis |
| Mycophenolate | — | IMP dehydrogenase → ↓ purine synthesis | Lymphocyte-specific antiproliferative | GI upset, bone marrow suppression |
| Glucocorticoids | GR | NF-κB, ↓ cytokines, apoptosis of lymphocytes | Broad immunosuppression | Cushingoid, HTN, hyperlipidemia, hyperglycemia — NO gingival hyperplasia |
| Basiliximab | — | IL-2 receptor (CD25) | Blocks IL-2 signaling | Hypersensitivity |
| OKT3 (Muromonab) | — | CD3 on T cells | Blocks TCR signaling | Cytokine release syndrome |
Cyclosporine: Cyclophilin → calcineurin inhibited → ↓IL-2
Tacrolimus: FKBP → calcineurin inhibited → ↓IL-2
Sirolimus: FKBP → mTOR inhibited → ↓IL-2 effect (NOT transcription)
Key distinction: Sirolimus also binds FKBP but hits mTOR, NOT calcineurin. Question specifies "inhibits IL-2 transcription" → rules out sirolimus immediately.
| Drug | Class |
|---|---|
| Cyclosporine | Immunosuppressant |
| Nifedipine (CCB) | Antihypertensive |
| Phenytoin | Antiepileptic |
Cyclosporine causes HTN → often co-prescribed with nifedipine → double gingival hyperplasia risk
| Drug | Nephrotoxic? |
|---|---|
| Cyclosporine | YES (afferent arteriole vasoconstriction) |
| Tacrolimus | YES (same mechanism) |
| Sirolimus | Less nephrotoxic; often used to spare kidneys |
| Azathioprine/MMF | No direct nephrotoxicity |
an antimetabolite that blocks purine synthesis and subsequently inhibits the proliferation of lymphocytes. It does not inhibit the transcription of interleukin-2. Important adverse effects of azathioprine include bone marrow suppression (leading to pancytopenia), hepatotoxicity, acute pancreatitis, infection, malignancy, and fetal harm in pregnant women. Azathioprine is not known to cause any of the adverse effects observed in this patient. (Choice F) Mycophenolate mofetil is an immunosuppressant drug that is commonly used for transplant rejection prophylaxis. It inhibits inosine monophosphate dehydrogenase, which impairs lymphocyte purine synthesis and subsequently inhibits lymphocyte proliferation. Mycophenolate mofetil does not inhibit the transcription of interleukin-2. Side effects of this drug include hypertension and hyperlipidemia, as seen in this patient. However, it is not known to cause gingival hyperplasia. Further important adverse effects of mycophenolate mofetil include first-trimester pregnancy loss and congenital malformations, infection, malignancy, neutropenia, and hyperglycemia. this also include
| Drug | Binds | Inhibits | Blocks IL-2 transcription? | Unique Side Effects |
|---|---|---|---|---|
| Cyclosporine | Cyclophilin | Calcineurin → ↓NFAT | YES | Gingival hyperplasia, nephrotoxicity, HTN, hyperlipidemia, hirsutism |
| Tacrolimus | FKBP | Calcineurin → ↓NFAT | YES | New-onset DM, nephrotoxicity, neurotoxicity, HTN, hyperlipidemia — NO gingival hyperplasia |
| Sirolimus | FKBP | mTOR → ↓IL-2 response | NO (blocks response, not transcription) | HTN, hyperlipidemia, pancytopenia, insulin resistance — NO gingival hyperplasia |
| Azathioprine | — | Purine synthesis (via 6-MP) | NO | Bone marrow suppression, hepatotoxicity, pancreatitis, teratogenic — NO gingival hyperplasia |
| Mycophenolate | — | IMP dehydrogenase → ↓purines | NO | HTN, hyperlipidemia, neutropenia, hyperglycemia, teratogenic (1st trimester loss + malformations) — NO gingival hyperplasia |
| Glucocorticoids | GR | NF-κB, ↓ cytokines | NO | Cushingoid, HTN, hyperlipidemia, hyperglycemia — NO gingival hyperplasia |
| Basiliximab | — | IL-2 receptor (CD25) | NO | Hypersensitivity reactions |
Cyclosporine → Cyclophilin → calcineurin blocked → NFAT can't enter nucleus → NO IL-2 mRNA
Tacrolimus → FKBP → calcineurin blocked → NFAT can't enter nucleus → NO IL-2 mRNA
Sirolimus → FKBP → mTOR blocked → IL-2 signal can't drive proliferation
Azathioprine → 6-MP → no purines → no DNA synthesis → no lymphocyte division
Mycophenolate → IMPDH → no purines → no DNA synthesis → lymphocyte-specific
Azathioprine and Mycophenolate both block purine synthesis but via different enzymes. Neither touches IL-2 transcription.
| Drug | Fetal Risk |
|---|---|
| Mycophenolate | 1st trimester loss + congenital malformations — stop before pregnancy |
| Azathioprine | Fetal harm — avoid in pregnancy |
| Sirolimus | Avoid in pregnancy |
| Tacrolimus/Cyclosporine | Use with caution — relatively safer options if transplant essential |
| Drug | Class |
|---|---|
| Cyclosporine | Immunosuppressant |
| Nifedipine (CCB) | Antihypertensive |
| Nifedipine is often co-prescribed with cyclosporine → doubles the risk | — |
| Phenytoin | Antiepileptic |
Mnemonic: "Can Nifedipine Phyte?" = Cyclosporine, Nifedipine, Phenytoin
| Side Effect | Drug(s) |
|---|---|
| Gingival hyperplasia | Cyclosporine, Nifedipine, Phenytoin |
| New-onset diabetes | Tacrolimus, glucocorticoids, sirolimus |
| Nephrotoxicity | Cyclosporine, Tacrolimus |
| Pancreatitis | Azathioprine |
| Bone marrow suppression | Azathioprine, mycophenolate (neutropenia) |
| Teratogenicity | Mycophenolate (most dangerous), azathioprine |
| HTN + hyperlipidemia | Cyclosporine, tacrolimus, sirolimus, MMF, glucocorticoids |
| Hirsutism | Cyclosporine |
| Neurotoxicity | Tacrolimus |